Karyopharm Therapeutics (KPTI) Income from Continuing Operations (2012 - 2025)
Karyopharm Therapeutics (KPTI) reported Income from Continuing Operations of 90185000.0 for Q4 2025, up 97.49% on a YoY basis from 45665000.0 in Q4 2024, and up 372.24% quarter-over-quarter from 33127000.0 in Q3 2025.
Karyopharm Therapeutics (KPTI) Income from Continuing Operations (2012 - 2025) Analysis & Trends
Karyopharm Therapeutics has reported Income from Continuing Operations for 14 years, with the latest figure at 90185000.0 in Q4 2025.
- For the quarter ending Q4 2025, Income from Continuing Operations rose 97.49% year-over-year to 90185000.0; the trailing twelve-month figure through Dec 2025 stood at 3656000.0 (down 15995.65% YoY), and the FY2025 full-year result was 3656000.0, down 15995.65% from the prior year.
- Income from Continuing Operations for Q4 2025 stood at 90185000.0, up from 33127000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 90185000.0 in Q4 2025, with the low at 57414000.0 in Q1 2021.
- Historically, Income from Continuing Operations has averaged 20301800.0 across 5 years, with a median of 35415000.0 in 2022.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations soared 209.21% — and 2025, when it slumped 256.57%.
- Karyopharm Therapeutics' Income from Continuing Operations stood at 68772000.0 in 2021, then slumped by 155.99% to 38506000.0 in 2022, then declined by 8.59% to 41814000.0 in 2023, then soared by 209.21% to 45665000.0 in 2024, then jumped by 97.49% to 90185000.0 in 2025.
- The last three Income from Continuing Operations figures came in at 90185000.0 (Q4 2025), 33127000.0 (Q3 2025), and 37252000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -56.48 Mn |
| 10 | Karyopharm Therapeutics | 95.31 Mn | 31.56 Mn | 32.74 Mn | 90.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 90.19 Mn |
| Sep 30, 2025 | -33.13 Mn |
| Jun 30, 2025 | -37.25 Mn |
| Mar 31, 2025 | -23.46 Mn |
| Dec 31, 2024 | 45.67 Mn |
| Sep 30, 2024 | -32.07 Mn |
| Jun 30, 2024 | 23.79 Mn |
| Mar 31, 2024 | -37.36 Mn |
| Dec 31, 2023 | -41.81 Mn |
| Sep 30, 2023 | -34.51 Mn |
| Jun 30, 2023 | -32.63 Mn |
| Mar 31, 2023 | -34.13 Mn |
| Dec 31, 2022 | -38.51 Mn |
| Sep 30, 2022 | -36.32 Mn |
| Jun 30, 2022 | -49.06 Mn |
| Mar 31, 2022 | -41.40 Mn |
| Dec 31, 2021 | 68.77 Mn |
| Sep 30, 2021 | -51.81 Mn |
| Jun 30, 2021 | -53.58 Mn |
| Mar 31, 2021 | -57.41 Mn |